






Twenty years of LASSBio, the laboratory of evaluation and  
synthesis of bioactive substances!
Considering its fruitful contribution to the search for new molecules that potentially can be drugs, 
LASSBio, situated at the Federal University of Rio de Janeiro, has been representing the best of Brazilian 
Medicinal Chemistry for twenty years.
LASSBio is Professor Eliezer Barreiro’s dream that comes true. Although formally created on April 
19, 1994, the work of the previous group had started years before, as soon as Professor Eliezer returned from 
his PhD in France. Thanks to his hardworking and idealistic personality inspiring his students and colleagues, 
many obstacles have been overcome from that time on and the success arose as a consequence of compe-
tence, discipline and belief. Professors Lidia Moreira Lima and Carlos Manssour Fraga have been sharing 
the responsibility of LASSBio performance since they got their PhD under Professor Eliezer supervision.
Last September 25-26, a Workshop was held in the Federal University of Rio de Janeiro to celebrate 
20 years of this Laboratory. More than a confraternization party, it represented a historical event and an ex-
ample to new generations. 
It is worth to note that more than one hundred of masters and doctors had been graduated in this Labo-
ratory since it was born. Most of those graduated professionals are now in academia and have been nucleating 
new groups, expanding the knowledge they got from the original nucleus. 
Following Ford statement, that says “Coming together is a beginning, staying together is progress, and 
working together is success”, the group has joint together collaborators of many areas of knowledge, comprised 
by Drug Design, and succeeded. Many relevant scientific projects supported mainly by CNPq, FAPERJ, and 
also some pharmaceutical industries, allowed LASSBio to trigger the creation of INCt-INOFAR, National 
Institute of Science and Technology in drugs and medicines, a relevant and fruitful initiative supported by 
those financial agencies, constituting an example of organization that embraces teaching, knowledge genera-
tion, reflected by almost three hundred scientific papers, and important outreach activities. 
Working on the design of new drug candidates for pain, inflammation, asthma, central nervous sys-
tems, cardiovascular system, cancer, metabolic diseases, and neglected diseases, they registered 15 patents, 
including international ones. More than one thousand and five hundred molecules were synthesized and 
evaluated so far, intending to obtain drug candidates for one or more of those therapeutic areas, as mentioned 
Brazilian Journal of
Pharmaceutical Sciences 
before. This solid library of molecules has been built using specially approaches as molecular simplification, 
and hybridization, this latter addressed to obtain symbiotic effect through the interaction with more than 
one target. The group has also being using molecular modeling as an important tool for understanding the 
physico-chemical aspects and the mechanism of action of the new molecules. This is a legacy for the present 
and future generations working on drug design and provides means to achieve Professor Eliezer´s goal: “To 
discover a drug that speaks Portuguese!” 
On behalf of Professor Eliezer Barreiro, congratulations to all who are partners in those 20 years of 
success!
Long live to LASSBio!
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